RESEARKA

The cited A/B receipts support a specific working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.84 [95% CI, 0.62-1.16]; P=0.29). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.

Citation Support

• source_1 SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies
• source_2 Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review
• source_3 Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2
• source_4 Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction
• source_5 Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF